Daniel Allen Gold Sells 800,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares in the company, valued at approximately $473,388,414.30. This represents a 5.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total value of $436,766.40.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The shares were sold at an average price of $34.00, for a total transaction of $21,276,622.00.

Roivant Sciences Stock Performance

ROIV stock opened at $35.03 on Thursday. The company has a market capitalization of $25.20 billion, a PE ratio of -58.38 and a beta of 1.10. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $35.90. The company’s 50 day moving average price is $30.00 and its two-hundred day moving average price is $27.11.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter last year, the firm earned ($0.29) EPS. On average, research analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Analyst Ratings Changes

ROIV has been the topic of several analyst reports. Guggenheim lifted their price objective on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. TD Cowen increased their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Citigroup lifted their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Finally, Sanford C. Bernstein initiated coverage on Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.59.

Institutional Trading of Roivant Sciences

Several large investors have recently modified their holdings of the business. Morgan Stanley raised its position in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after purchasing an additional 14,036,696 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Roivant Sciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after buying an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP grew its position in shares of Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares during the last quarter. State Street Corp increased its stake in shares of Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after buying an additional 911,827 shares during the period. Finally, UBS Group AG increased its stake in shares of Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.